References
- Wild PS, Zeller T, Schillert A, et al. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet 2011;4:403-12
- Desai NK, Wilson DP. Lysosomal acid lipase deficiency. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth, MA: MDText.com, Inc.; 2000 [updated 2016 Jun 22]. https://www.ncbi.nlm.nih.gov/books/NBK395569/. Accessed May 8, 2017
- Burton BK, Deegan PB, Enns GM, et al. Clinical features of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2015;61:619-25
- Porto AF. Lysosomal acid lipase deficiency: diagnosis and treatment of Wolman and cholesteryl ester storage diseases. Pediatr Endocrinol Rev 2014;12(S1):125-32
- Su K, Donaldson E, Sharma R. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa. Appl Clin Genet 2016;9:157-67
- Frampton JE. Sebelipase Alfa: A review in lysosomal acid lipase deficiency. Am J Cardiovasc Drugs 2016;16:461-8
- Valayannopoulos V, Malinova V, Honzík T, et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol 2014;61:1135-42
- Sheridan C. FDA approves ‘farmaceutical’ drug from transgenic chickens. Nat Biotechnol 2016;34:117-9
- Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013;58:950-7
- FDA U.S. Food & drug Administration. FDA News Release: FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476013.htm. Accessed May 8, 2017
- Burton BK, Silliman N, Marulkar S. Progression of liver disease in children and adults with lysosomal acid lipase deficiency. Curr Med Res Opin 2017; in press doi: 10.1080/03007995.2017.1309371
- Reiner Ž, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency—an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014;235:21-30
- Baratta F, Pastori D, Del Ben M, et al. Reduced lysosomal acid lipase activity in adult patients with Non-alcoholic fatty liver disease. EBioMedicine 2015;2:750-4
- Selvakumar PK, Kabbany MN, Lopez R, et al. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Dig Liver Dis 2016;48:909-13
- Hamilton J, Jones I, Srivastava R, et al. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 2012;413:1207-10
- Carr PD, Ollis DL. Alpha/beta hydrolase fold: an update. Protein Pept Lett 2009;16:1137-48
- ClinicalTrials.gov [Internet]. A service of the U.S. National Institutes of Health. 2016 https://clinicaltrials.gov/ct2/show/NCT02926872. Accessed May 8, 2017
- SWISS MODEL [Internet]. Universität Basel, The Center for Molecular Life Sciences. 2014 https://swissmodel.expasy.org/. Accessed March 31, 2017
- NCBI (National Center for Biotechnology Information) [Internet]. U.S. National Library of Medicine. 1992 https://www.ncbi.nlm.nih.gov/. Accessed May 8, 2017
- RCSB Protein Data Bank [Internet]. Research Collaboratory for Structural Bioinformatics. Accession number: 1K8Q. 2002 http://www.rcsb.org/pdb/explore/explore.do?structureId=1k8q. Accessed May 8, 2017
- Prosite. [Internet]. ExPASy Bioinformatics Resource Portal. Database of protein domains, families and functional sites. http://prosite.expasy.org/. 2011 Accessed May 8, 2017
- Ginsberg HN, Le NA, Short MP, et al. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692-7
- Cummings MH, Watts GF. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem 1995;41:111-4